journal article·2024-05

A Multichannel Metabolic Pathway Interference Strategy for Complete Energy Depletion‐Mediated Cancer Therapy

He Ding, Jianye Wei, Linyang Fang, Lili Feng, Shili Gai, Fei He, Linzhi Wu, Ziaur Rehman, Piaoping Yang

Advanced Functional Materials· Volume 34· Issue 19
Publisher page

Abstract

Abstract Hydrogen sulfide (H2S) is being progressively integrated as an emerging inhibitor of the electron transport chain in energy interference‐based tumor therapy. However, metabolic reprogramming in cancer cells causes both oxidative phosphorylation (OXPHOS) and glycolysis to occur simultaneously, which contributes to the ineffective therapeutic effect of blocking a single pathway. To achieve complete suppression of energy production, an inorganic H2S donor ZnS@ZIF‐8@CaP nanoparticle (ZSZC NP) carrying Ca and Zn is constructed for achieving simultaneous interference of OXPHOS and glycolysis. The core–shell ZSZC nanoparticles can break down in the tumor microenvironment. This leads to a sustained H2S release and calcium overload to disrupt the normal functioning of mitochondria by inhibiting the expression of cytochrome c and causing damage to mitochondrial membrane potential. Meanwhile, the presence of Zn2+ hinders the typical process of glycolysis by impeding the functioning of lactate dehydrogenase and glyceraldehyde‐3‐phosphate dehydrogenase. The synchronous interference of OXPHOS and glycolysis hampers the energy supply to cancer cells. Additionally, H2S and calcium overload can expedite tumor necrosis in vivo by inducing cellular acidification and calcification. Therefore, this energy‐blocking strategy will completely deplete the energy reserves of cancer cells and provide new insights for exploring bioenergetic inhibition as a treatment approach.
Source: crossref · Quality: baseline

Research context

OpenAlex topics: Nanoplatforms for cancer theranostics · Sulfur Compounds in Biology · Cancer, Hypoxia, and Metabolism

SciVX discovery tags are terminology-based. OpenAlex topics are source-provided classifications.

Affiliations

Key Laboratory of Superlight Materials and Surface Technology Ministry of Education College of Materials Science and Chemical Engineering Harbin Engineering University Harbin 150001 P. R. China

College of Aerospace and Civil Engineering Harbin Engineering University Harbin 150001 P. R. China

Department of Chemistry Quaid‐i‐Azam University Islamabad 45320 Pakistan

Funding

National Natural Science Foundation of China · Natural Science Foundation of Heilongjiang Province · China Postdoctoral Science Foundation · Heilongjiang Postdoctoral Science Foundation · Fundamental Research Funds for the Central Universities

References (58)

Show source-provided references
1. 10.3389/fimmu.2022.95547610.3389/fimmu.2022.955476 ↗
2. 10.4062/biomolther.2017.18410.4062/biomolther.2017.184 ↗
3. Crunkhorn S. · Nat Rev Drug Discov. · 2018 · 17 · 708
4. 10.1002/anie.20210430410.1002/anie.202104304 ↗
5. 10.3390/ijms2408707610.3390/ijms24087076 ↗
6. 10.1021/acsami.2c1627810.1021/acsami.2c16278 ↗
7. 10.1002/advs.20210099710.1002/advs.202100997 ↗
8. 10.1016/j.nantod.2022.10146110.1016/j.nantod.2022.101461 ↗
9. 10.1021/acsnano.1c1023110.1021/acsnano.1c10231 ↗
10. 10.1016/j.jconrel.2022.06.02210.1016/j.jconrel.2022.06.022 ↗
11. 10.7150/thno.6754310.7150/thno.67543 ↗
12. 10.1016/j.mtbio.2022.10044910.1016/j.mtbio.2022.100449 ↗
13. 10.1007/s12274-022-4237-210.1007/s12274-022-4237-2 ↗
14. 10.1016/j.semcancer.2022.02.00210.1016/j.semcancer.2022.02.002 ↗
15. 10.1111/bph.1236910.1111/bph.12369 ↗
16. 10.1016/j.redox.2020.10156410.1016/j.redox.2020.101564 ↗
17. 10.1002/adhm.20210198410.1002/adhm.202101984 ↗
18. 10.1016/j.actbio.2023.03.03610.1016/j.actbio.2023.03.036 ↗
19. Li J. · Small · 2020 · 16 · 39
20. Li M. · Adv. Mater. · 2023 · 35 · 29
21. 10.1021/acsami.2c1584410.1021/acsami.2c15844 ↗
22. 10.1002/adfm.20200799110.1002/adfm.202007991 ↗
23. 10.1002/advs.20220106910.1002/advs.202201069 ↗
24. 10.1002/smll.20210616810.1002/smll.202106168 ↗
25. 10.1002/adma.20210403710.1002/adma.202104037 ↗
26. 10.7150/ijbs.4785010.7150/ijbs.47850 ↗
27. 10.1016/j.apsb.2016.11.00110.1016/j.apsb.2016.11.001 ↗
28. 10.1016/j.ccr.2023.21505010.1016/j.ccr.2023.215050 ↗
29. 10.1007/s40820-022-00894-610.1007/s40820-022-00894-6 ↗
30. 10.1002/adma.20210122310.1002/adma.202101223 ↗
31. Dong Z. · Chem. · 2020 · 33
32. 10.1002/adma.20200742610.1002/adma.202007426 ↗
33. 10.1016/j.colsurfb.2023.11333010.1016/j.colsurfb.2023.113330 ↗
34. 10.1002/adfm.20230359610.1002/adfm.202303596 ↗
35. 10.1016/j.biomaterials.2022.12136910.1016/j.biomaterials.2022.121369 ↗
36. 10.1002/adhm.20230038510.1002/adhm.202300385 ↗
37. 10.1016/j.chempr.2019.06.00310.1016/j.chempr.2019.06.003 ↗
38. Pupo E. · Biol. Med. · 2011 · 51 · 1765
39. 10.1016/j.apsb.2022.08.00810.1016/j.apsb.2022.08.008 ↗
40. 10.1002/anie.20160136410.1002/anie.201601364 ↗
41. 10.3390/bios1212114510.3390/bios12121145 ↗
42. 10.1016/j.semcancer.2022.11.00710.1016/j.semcancer.2022.11.007 ↗
43. Wu S. · Adv. Sci. · 2021 · 9 · 7
44. 10.1038/s41467-022-30436-y10.1038/s41467-022-30436-y ↗
45. Duan F. · Adv. Mater. · 2023 · 35 · 17
46. 10.1002/smll.20220492610.1002/smll.202204926 ↗
47. 10.1080/15548627.2021.187634210.1080/15548627.2021.1876342 ↗
48. 10.1046/j.1471-4159.2003.01678.x10.1046/j.1471-4159.2003.01678.x ↗
49. 10.7150/thno.2036310.7150/thno.20363 ↗
50. 10.1002/smll.20140351710.1002/smll.201403517 ↗
51. 10.1186/s12951-022-01262-710.1186/s12951-022-01262-7 ↗
52. 10.1016/j.matdes.2022.11100810.1016/j.matdes.2022.111008 ↗
53. 10.7150/thno.4507910.7150/thno.45079 ↗
54. 10.1016/j.nantod.2022.10158510.1016/j.nantod.2022.101585 ↗
55. 10.7150/thno.4298110.7150/thno.42981 ↗
56. 10.1021/acsami.2c1826710.1021/acsami.2c18267 ↗
57. 10.1002/anie.20220083010.1002/anie.202200830 ↗
58. 10.1007/s12274-023-5458-810.1007/s12274-023-5458-8 ↗